Teva Pharmaceutical Industries Ltd. said Tuesday the Food and Drug Administration approved its generic version of the heartburn drug Prevacid.

Teva will sell 15-milligram and 30-milligram delayed-release capsule versions of the drug.

Teva said the branded version of Prevacid had sales of about $2.97 billion in the 12 months ended June 30.

Shares of Israel-based Teva fell 43 cents to close at $52.77.